ArticleProbiotics and antimicrobial proteins2025
Lactiplantibacillus plantarum ZJ316 Alleviates Helicobacter pylori-Induced Intestinal Inflammation by Sustaining Intestinal Homeostasis.
Article in Probiotics and antimicrobial proteins, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- AdjuvantMicrobiology spectrum · 2026Trial
- Review
- Conventional and Novel Approaches to Establishing Mouse Models of Gastric Cancer in the Past, Present, and Potential Post-H. Pylori Infection Era.Biological procedures online · 2026Review
- ILC imbalance - a new piece in the gut-kidney axis puzzle.Frontiers in immunology · 2026Review
- Synergistic effects of Bifidobacterium longum subsp. infantis B8762 and milk-derived osteopontin on male reproductive health in mice.Journal of the science of food and agriculture · 2025Article
- Gastrointestinal microbiota in treatment of gastric precancerous lesions and gastric cancer by Western and traditional Chinese medicine.World journal of clinical oncology · 2025Review
- Probiotic Potentials and Protective Effects ofNutrients · 2025Article
- Microplastics and probiotics: Mechanisms of interaction and their consequences for health.AIMS microbiology · 2025Review
- Oral pathogens meet the gut microbiome: new mechanistic insights on systemic disease.Frontiers in cellular and infection microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Helicobacter pylori (H. pylori) infection poses significant risks for gastric cancer and intestinal inflammation, yet effective prevention strategies for intestinal inflammation remain elusive. Here, we aimed to investigate the protective effects and underlying mechanisms of Lactiplantibacillus plantarum ZJ316 (L. plantarum ZJ316) in a mouse model of H. pylori-induced intestinal inflammation. The reverse transcription‑quantitative polymerase chain reaction (RT-qPCR) analysis showed that treatment with L. plantarum ZJ316 significantly upregulated the mRNA levels of tight junction proteins, including Zonula occludens-1 (ZO-1), Occludin, and Claudin-1, while simultaneously decreasing the expression levels of pro-inflammatory cytokines interleukin-1β (IL-1β), interferon-γ (IFN-γ), and tumor necrosis factor-α (TNF-α). Additionally, 16S rDNA sequencing analysis revealed that administration of L. plantarum ZJ316 reduced relative abundance of pathogenic bacteria, Staphylococcus and Desulfovibrio by 69% and 42%, respectively, while enhancing beneficial bacteria including Ligilactobacillus, Akkermansia, and Lactobacillus associated with short-chain fatty acids (SCFAs) synthesis by 88%, 85%, and 16%, respectively. Gas chromatography-mass spectrometry (GC-MS) analysis confirmed L. plantarum ZJ316 restored SCFA levels reduced by H. pylori infection. In vitro, L. plantarum ZJ316 inhibited the IκBα/NF-κB pathway, thereby reducing TNF-α and IL-8 production in HT-29 cells following H. pylori infection. These findings collectively suggest that L. plantarum ZJ316 ameliorates H. pylori-induced intestinal inflammation by enhancing gut barrier function, improving flora structure, increasing SCFA levels, and mitigating inflammation through NF-κB pathway inhibition, offering promise for therapeutic development.
Indexed as
Identifiers
39948232What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.